Trastuzumab biosimilar Ogivri approved in Canada

Biosimilares/Novedades | Posted 07/06/2019 post-comment0 Post your comment

India-based biologicals specialist Biocon and US-based partner Mylan announced on 22 May 2019 that Health Canada had approved Mylan’s trastuzumab biosimilar Ogivri.

health budget cuts 2 V13l06

Trastuzumab is a monoclonal antibody that interferes with the human epidermal growth factor receptor 2 (HER2)/neu receptor. In some cancers, notably certain types of breast cancer, HER2 is overexpressed, and causes cancer cells to reproduce uncontrollably. Trastuzumab is therefore used to treat certain breast cancers.

Ogivri is a biosimilar of Roche’s Herceptin (trastuzumab). It was co-developed with Biocon, for the treatment of HER2-overexpressing breast cancer and metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma).

Ogivri is the first trastuzumab biosimilar approved in Canada and the second biosimilar from Mylan and Biocon’s joint portfolio approved in the market.

The approval by Health Canada was based on robust data from structural and functional characterization using multiple orthogonal techniques, non-clinical studies and pharmacokinetic evaluation in healthy subjects and patients and a safety, efficacy and immunogenicity study in relevant patient populations, which compared Ogivri to Herceptin. The data, according to Biocon/Mylan, ‘demonstrated that Ogivri is highly similar to Herceptin with no clinically meaningful differences in terms of efficacy, safety, purity and potency’.

Biocon and Mylan’s trastuzumab biosimilar is currently approved in more than 65 countries around the world. The companies gained European approval in December 2018 [1], after a positive recommendation by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) in October 2018 [2]. The pair also received approval for Ogivri (MYL‑1401O) from the US Food and Drug Administration (FDA) and from the Brazilian Health Surveillance Agency’s (Agência Nacional de Vigilância Sanitária, ANVISA) in December 2017 [3, 4].

Related articles
Biosimilars of trastuzumab

Canadian approved biosimilars

References
1. GaBI Online - Generics and Biosimilars Initiative. Biosimilars approved in Europe [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2019 Jun 7]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Europe
2. GaBI Online - Generics and Biosimilars Initiative. Mylan gains nod for Ogivri and launches Hulio in Europe [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2019 Jun 7]. Available from: www.gabionline.net/Biosimilars/News/Mylan-gains-nod-for-Ogivri-and-launches-Hulio-in-Europe
3. GaBI Online - Generics and Biosimilars Initiative. FDA approves trastuzumab biosimilar Ogivri [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2019 Jun 7]. Available from: www.gabionline.net/Biosimilars/News/FDA-approves-trastuzumab-biosimilar-Ogivri
4. GaBI Online - Generics and Biosimilars Initiative. Trastuzumab biosimilars receive EMA and ANVISA approval [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2019 Jun 7]. Available from: www.gabionline.net/Biosimilars/News/Trastuzumab-biosimilars-receive-EMA-and-ANVISA-approval

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2019 Pro Pharma Communications International. All Rights Reserved.

Source: Biocon

comment icon Comments (0)
Post your comment
Related content
Etanercept biosimilars delayed until 2029 in US
Etanercept V14H14
Biosimilares/Novedades Posted 14/01/2022
Canada approves filgrastim biosimilar Nypozi
Filgrastim Grastofil V13H23
Biosimilares/Novedades Posted 14/01/2022
New Zealand announces funding for adalimumab biosimilar
02 AA010638
Biosimilares/Novedades Posted 17/12/2021
China approves three bevacizumab copy biologicals
Bevacizumab 2 V14f01
Biosimilares/Novedades Posted 10/12/2021
Most viewed articles
Sobre GaBI
INICIO/Sobre GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
INICIO/Directrices Posted 08/10/2010